Many studies had shown that IGF2BP3 was overexpressed in various cancers, including gastric cancer, lymphoid malignancies, nasopharyngeal cancer, and renal cell carcinoma [13–16], and that its overexpression correlates with a poor prognosis for overall survival. Here, IGF2BP3 is linked to cancer.